Trials Sponsors Conditions Drugs Pricing

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Keywords

unspecified adult solid tumor, protocol specific

Interventions

pralatrexateDrug

probenecidDrug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Histologically confirmed cancer that is potentially incurable by standard chemotherapy, radiotherapy, or surgical procedures * Failed prior first-line therapy (patients are also eligible if no effective first-line therapy exists) * Previously treated or clinically stable brain metastases are allowed * No leukemia or lymphoma * No clinically significant pleural effusions or ascites PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 70-100% Life expectancy: * Not specified Hematopoietic: * WBC at least 4,000/mm\^3 * Platelet count at least 160,000/mm\^3 * Hemoglobin greater than 10 g/dL * Serum and RBC folate normal Hepatic: * Bilirubin no greater than 1.5 mg/dL * SGOT or SGPT less than 2 times upper limit of normal Renal: * Creatinine no greater than 1.2 mg/dL OR * Creatinine clearance at least 60 mL/min Cardiovascular: * No unstable angina * No congestive heart failure * No cardiac arrhythmia Other: * Homocysteine normal * No grade III or IV edema * Not pregnant or nursing * Fertile patients must use effective contraception during and for 6 months after study PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * See Disease Characteristics * At least 3 weeks since prior chemotherapy (4 weeks for nitrosoureas or mitomycin) and recovered Endocrine therapy: * Not specified Radiotherapy: * See Disease Characteristics * At least 3 weeks since prior radiotherapy to bone marrow-containing areas and recovered Surgery: * See Disease Characteristics * No prior pneumonectomy Other: * No concurrent folic acid or potentially nephrotoxic agents

Sponsors & Collaborators

Memorial Sloan Kettering Cancer Center
Otherlead
National Cancer Institute (NCI)
NIHcollaborator

Study Sites (1)

Memorial Sloan-Kettering Cancer Center

New York, New York, 10021, United States

MeSH Terms

Interventions

10-propargyl-10-deazaaminopterinProbenecid

Intervention Hierarchy (Ancestors)

SulfonamidesAmidesOrganic ChemicalsSulfonesSulfur Compounds

Study Officials

Naiyer Rizvi, MD
Memorial Sloan Kettering Cancer Center
STUDY CHAIR

Study Design

Study Type: interventional
Phase: phase 1
Purpose: TREATMENT
Sponsor Type: OTHER

Study Record Dates

First Submitted

September 13, 2001

First Posted

January 27, 2003

Study Start

May 2001

Date type not reported

This date has not been verified as actual or estimated.

Study Completion

April 2003

Actual (reported)

10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Source record

Locations